Free Newsletter
Hinting at layoffs, Pfizer extends severance
One hint that Pfizer layoffs will only continue: The company extended its severance-package program, which was due to expire at year's end, through mid-2009, because the drugmaker couldn't treat new layoffs differently from those cut previously. And according to sources close to the action, those layoffs probably would include a large number of sales reps.
Meanwhile, Pfizer is also considering spinning off some of the research units that it put on the "eliminate" list two weeks ago, Pharmalot reports. Plus, the company might buy a "brand-name biotech." As you know, almost every time a biotech appears to be on the block, Pfizer is rumored to be among the pharma firms kicking tires. Which target might actually prove out is a mystery, though the gossip says Pfizer might take another look at Biogen Idec.
A new round of job cuts would add to the 10,000 Pfizer announced in January 2007 as part of a major restructuring program that also included plant closures and research-center shutdowns.
- read the post at Pharmalot
Related Articles:
Pfizer layoff talk boosts stock
Pfizer reorganizes, leaves Ann Arbor
Pfizer unveils realignment of global ops
Pfizer drops heart research in R&D revamp
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: